Literature DB >> 27427866

The evolutionary scenario of hepatocellular carcinoma in Italy: an update.

Laura Bucci1, Francesca Garuti1, Barbara Lenzi1, Anna Pecorelli2, Fabio Farinati3, Edoardo G Giannini4, Alessandro Granito2, Francesca Ciccarese5, Gian Lodovico Rapaccini6, Maria Di Marco7, Eugenio Caturelli8, Marco Zoli2, Franco Borzio9, Rodolfo Sacco10, Calogero Cammà11, Roberto Virdone12, Fabio Marra13, Martina Felder14, Filomena Morisco15, Luisa Benvegnù16, Antonio Gasbarrini17, Gianluca Svegliati-Baroni18, Francesco Giuseppe Foschi19, Gabriele Missale20, Alberto Masotto21, Gerardo Nardone22, Antonio Colecchia23, Mauro Bernardi1, Franco Trevisani1.   

Abstract

BACKGROUND & AIMS: Epidemiology of hepatocellular carcinoma is changing worldwide. This study aimed at evaluating the changing scenario of aetiology, presentation, management and prognosis of hepatocellular carcinoma in Italy during the last 15 years.
METHODS: Retrospective analysis of the ITA.LI.CA (Italian Liver Cancer) database including 5192 hepatocellular carcinoma patients managed in 24 centres from 2000 to 2014. Patients were divided into three groups according to the date of cancer diagnosis (2000-2004, 2005-2009 and 2010-2014).
RESULTS: The main results were as follows: (i) progressive patient aging; (ii) progressive expansion of non-viral cases and, namely, of "metabolic" hepatocellular carcinomas; (iii) increasing proportion of hepatocellular carcinoma diagnosed during a correct (semi-annual) surveillance programme; (iv) favourable cancer stage migration; (v) increased use of radiofrequency ablation to the detriment of percutaneous ethanol injection; (vi) improved outcomes of ablative and transarterial treatments; (vii) improved overall survival (adjusted for the lead time in surveyed patients), particularly after 2009, of both viral and non-viral patients presenting with an early- or intermediate-stage hepatocellular carcinoma.
CONCLUSIONS: During the last 15 years several aetiological and clinical features of hepatocellular carcinoma patients have changed, as their management. The observed improvement of overall survival was owing both to the wider use of semi-annual surveillance, expanding the proportion of tumours that qualified for curative treatments, and to the improved outcome of loco-regional treatments.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  epidemiology; hepatocellular carcinoma; survival; treatment

Mesh:

Substances:

Year:  2016        PMID: 27427866     DOI: 10.1111/liv.13204

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  29 in total

1.  Hepatocellular carcinoma surveillance: an open question.

Authors:  Maurizio Biselli; Francesca Garuti; Andrea Neri
Journal:  Hepatobiliary Surg Nutr       Date:  2019-08       Impact factor: 7.293

Review 2.  Patients with Barcelona Clinic Liver Cancer Stages B and C Hepatocellular Carcinoma: Time for a Subclassification.

Authors:  Rita Golfieri; Irene Bargellini; Carlo Spreafico; Franco Trevisani
Journal:  Liver Cancer       Date:  2018-06-27       Impact factor: 11.740

3.  Use of Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis: A Systematic Review and Meta-Analysis.

Authors:  Erin Wolf; Nicole E Rich; Jorge A Marrero; Neehar D Parikh; Amit G Singal
Journal:  Hepatology       Date:  2020-11-20       Impact factor: 17.425

Review 4.  Experience with regorafenib in the treatment of hepatocellular carcinoma.

Authors:  Alessandro Granito; Antonella Forgione; Sara Marinelli; Matteo Renzulli; Luca Ielasi; Vito Sansone; Francesca Benevento; Fabio Piscaglia; Francesco Tovoli
Journal:  Therap Adv Gastroenterol       Date:  2021-05-28       Impact factor: 4.409

5.  Deciphering the epidemiology of hepatocellular carcinoma through the passage of time: A study of 1,401 patients across 3 decades.

Authors:  George Boon-Bee Goh; James Weiquan Li; Pik-Eu Chang; Khuan-Yew Chow; Chee-Kiat Tan
Journal:  Hepatol Commun       Date:  2017-06-14

6.  Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis.

Authors:  Carla Rognoni; Oriana Ciani; Silvia Sommariva; Irene Bargellini; Sherrie Bhoori; Roberto Cioni; Antonio Facciorusso; Rita Golfieri; Annagiulia Gramenzi; Vincenzo Mazzaferro; Cristina Mosconi; Francesca Ponziani; Rodolfo Sacco; Franco Trevisani; Rosanna Tarricone
Journal:  BMC Cancer       Date:  2018-07-05       Impact factor: 4.430

7.  New landscapes and horizons in hepatocellular carcinoma therapy.

Authors:  Melchiorre Cervello; Maria R Emma; Giuseppa Augello; Antonella Cusimano; Lydia Giannitrapani; Maurizio Soresi; Shaw M Akula; Stephen L Abrams; Linda S Steelman; Alessandro Gulino; Beatrice Belmonte; Giuseppe Montalto; James A McCubrey
Journal:  Aging (Albany NY)       Date:  2020-02-04       Impact factor: 5.682

8.  Long-Term Outcomes and Evaluation of Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Eradication by Direct-Acting Antiviral Treatment: All Kagawa Liver Disease Group (AKLDG) Study.

Authors:  Joji Tani; Tomonori Senoh; Akio Moriya; Chikara Ogawa; Akihiro Deguchi; Teppei Sakamoto; Kei Takuma; Mai Nakahara; Kyoko Oura; Tomoko Tadokoro; Shima Mimura; Koji Fujita; Hirohito Yoneyama; Hideki Kobara; Asahiro Morishita; Takashi Himoto; Akemi Tsutsui; Takuya Nagano; Koichi Takaguchi; Tsutomu Masaki
Journal:  Cancers (Basel)       Date:  2021-05-08       Impact factor: 6.639

Review 9.  Unique Features of Hepatitis B Virus-Related Hepatocellular Carcinoma in Pathogenesis and Clinical Significance.

Authors:  Sheng-Han Wang; Shiou-Hwei Yeh; Pei-Jer Chen
Journal:  Cancers (Basel)       Date:  2021-05-18       Impact factor: 6.639

Review 10.  Hepatocellular carcinoma in adult thalassemia patients: an expert opinion based on current evidence.

Authors:  Alessandra Mangia; Davide Bellini; Umberto Cillo; Andrea Laghi; Giuseppe Pelle; Vanna Maria Valori; Eugenio Caturelli
Journal:  BMC Gastroenterol       Date:  2020-08-03       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.